Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 5/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | APEX1 | P27695 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | RAD52 | P43351 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epigallocatechin SCHEMBL29870730 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| Epigallocatechin SCHEMBL12840936 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| Epigallocatechin SCHEMBL1972940 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| Epigallocatechin SCHEMBL1972938 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| Epigallocatechin SCHEMBL12285364 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| Epigallocatechin SCHEMBL19553 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| Gallocatechin SCHEMBL3872234 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| Epigallocatechin SCHEMBL20203645 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| (-)-Gallocatechin SCHEMBL1742127 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT | |
| Epigallocatechin SCHEMBL29929503 | 1.00 | BACE1 (1.00) | BACE1KDM4EPTGS1SNCAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618965-A1 | NOVEL OPHTHALMIC FORMULATION | Fertis India Pvt. Ltd. (IN) | 2025-09-24 | — | — | EP | claimed |
| EP-4380633-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | claimed |
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2024105703-A1 | NOVEL OPHTHALMIC FORMULATION | FERTIS INDIA PVT LTD (IN) | 2024-05-23 | — | — | WO | claimed |
| WO-2023191839-A9 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023191839-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4719497-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | Rayzebio, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12514939-B2 | Stable radiopharmaceutical compositions and uses thereof | ALPHA-9 ONCOLOGY, INC. (CA) | 2026-01-06 | — | — | US | disclosed |
| EP-4618965-A1 | NOVEL OPHTHALMIC FORMULATION | Fertis India Pvt. Ltd. (IN) | 2025-09-24 | — | — | EP | disclosed |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ALPHA-9 ONCOLOGY INC. (CA) | 2025-08-14 | — | — | US | disclosed |
| WO-2024249352-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | RAYZEBIO, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118831183-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11819556-B2 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230293737-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | RAYZEBIO, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293737-A1 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | TFRC, SLC39A14, EGFR | BACE1 1741/4885KDM4E 3658/4885PTGS1 4873/4885 |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RCN1, RABL6, QPCT | BACE1 2193/4885KDM4E 3904/4885PTGS1 4381/4885 |
| US-11819556-B2 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | BACE1 1741/4885KDM4E 3658/4885PTGS1 4873/4885 |
| US-11541134-B1 | Stabilized compositions of radionuclides and uses thereof | TFRC, SLC39A14, EGFR | BACE1 1741/4885KDM4E 3658/4885PTGS1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.